Antibiotice Iasi (ATB) will sell a new medical drug, the injectable nafcilin, on the US market, after being certified by the American drug regulatory agency FDA, and estimates an increase of exports to the USA by 36 pc next year, to USD 4.5 M, Mediafax informs. Antibiotice Iasi is already present on the US market with its generic drug ‘ampicillin’ in four doses and the active substance ‘nistatin,’ reads a press release sent to the Bucharest Stock Exchange (BVB) on Monday. The generic drug ‘injectable nafcillin’ is sold in doses of 1 gram and 2 grams. The FDA also licensed Antibiotice, in October, for the production flow of the injectable medicines belonging to the category of penicillins.
